#mid-market-sf

#mid-market-sf

In March 2026, US startups raised $19.06 billion across 630 deals, a significant decline of 64.4% year-over-year from March 2025's $53.5 billion, which was heavily influenced by OpenAI's $40 billion mega-round.

Launching a fund used to be a real test of endurance, with timelines often stretching across many months. The process demanded patience that many ambitious founders found difficult to sustain.

Freecash paid users to play mobile games while collecting sensitive information including race, religion, sexual orientation and health data, according to cybersecurity firm Malwarebytes.

"When I'm irritated, tired, stressed, or anxious, a nap literally cures everything. It really changed my life."

Dhruv Amin stated, 'We built a mobile app primarily to let our users who are building iOS apps preview their own app on their own device while developing it. [We] had no problems through December. Post December, we and everyone else in the category started getting our updates blocked.'

To find a building with this scale, flexibility, and existing group housing use in such a prime location is extraordinarily rare.

KB Home's forthcoming move will mark its return to the Phoenix area, where the company was headquartered for a few years in the 1960s before shifting its operations to Los Angeles.

Austin Nasso rebranded himself as a tech-savvy 'bro' comedian, attracting Silicon Valley's edge lords while maintaining a good-hearted and fun comedic style.

Goldman Sachs' Chief Equity Strategist Peter Oppenheimer has called the recent sell-off in U.S. tech stocks a rare 'buying opportunity,' suggesting that the current market conditions may favor investment in this sector.

"We were considering multiple forms of capital when we started. It just felt like the opportunity is so large that venture capital gives us the opportunity to take those risks upfront and have the possibility to generate an outsized return."

Helical's thesis is that bio foundation models, AI systems trained on vast genomic, transcriptomic, and proteomic datasets, have already crossed a quality threshold that makes computational hypothesis-testing meaningful in pharma research.